MLRagent

Inert/inactive ingredients may not be featured to overstate their value

AI-verifiedwarningBinding lawRaised as a question — a person decides

Rule

Inert or inactive ingredients cannot be given prominence that overstates their actual functional contribution to the drug.

Check

Look for emphasis (headlines, graphics, callouts) on inactive ingredients that implies therapeutic value; compare to their actual role.

Escalate when

Unclear whether the emphasis given to an inactive ingredient exceeds its true functional role.

Where this comes from

21 CFR 202.1(a)(4). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…information on the label of the product. (3) The advertisement shall not employ a fanciful proprietary name for the drug or any ingredient in such a manner as to imply that the drug or ingredient has some unique effectiveness or composition, when, in fact, the drug or ingredient is a common substance, the limitations of which are readily recognized when the drug or ingredient is listed by its established name. (4) The advertisement shall not feature inert or inactive ingredients in a manner that creates an impression of value greater than their true functional role in the formulation. (5) The advertisement shall not designate a drug or ingredient by a proprietary name that, because of similarity in spelling or pronunciation, may be confused with the proprietary name or the established name of a different drug or ingredient. (b)(1) If an advertisement for a prescription drug bears a proprietary name or designation for the drug or any ingredient thereof, the established name, if such there be, co…
Document
21 CFR 202.1
Version
2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved
2026-09-21 from www.ecfr.gov
Fingerprint
a542640a872b3f2702d549e8…